Arkema stock surges 2.5% and posts one of the strongest gains on the SBF 120
The specialty chemicals company advanced significantly on Friday, in a broadly supportive European market. The stock ranks high on the SBF 120 leaderboard, while the Paris index rises nearly 1% during the session.
A rebound of 2.49% that keeps the stock above its long-term moving averages
Arkema is trading at €59.75 during the session, up 2.49% compared to Thursday's close at €58.30. This rebound brings monthly performance to nearly 8%, confirming positive momentum over thirty days. Over one year, the stock remains slightly in decline (-2.69%), but the recent trajectory significantly attenuates this pullback.
The price is evolving above the 50-day MA (€57.89, +3.21% gap) and the 200-day MA (€56.91, +4.99% gap), reflecting a favorable technical setup over intermediate and long-term horizons. Conversely, it remains below the 20-day MA at €60.53, with a -1.29% gap: this level represents the first obstacle to watch in the near term. The RSI at 44 remains in neutral territory, with no overbought or buyer exhaustion signals, leaving room for the current movement to develop.
Solid half-year results lay the groundwork for Friday's momentum
To understand the backdrop, we must return to the second quarter 2026 results published on July 30th. EBITDA had grown 7.4% year-over-year to €391 million, with margins at 16.1%, in a challenging overall environment. Over the first half, revenue had declined 3.5% to €4,610 million and EBITDA fell 2.7% to €674 million, but full-year guidance was maintained, which reassured the market.
On Friday, the stock market context proves broadly favorable: the CAC 40 is up 0.95% during the session and the SBF 120 up 0.91%, providing fertile ground for portfolio holdings. With the VIX at 14.47, down from the previous day (15.21), appetite for risk remains intact. The resistance threshold at €62.35 represents the next level beyond the 20-day MA, while support at €54.20 provides significant cushioning in case of a reversal.
